FDA Inspection 1120265 — LILLY CENTRE FOR CLINICAL PHARMACOLOGY PTE LTD
The FDA completed an inspection of LILLY CENTRE FOR CLINICAL PHARMACOLOGY PTE LTD on Feb 7, 2020 in Singapore. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 7, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Singapore (Singapore)
Additional details
Clinical BA/BE